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Glutathione S-transferase Theta1 and Mu1 (GSTT1 and GSTM1) are involved in the metabolism and detoxification of a wide range
of potential environmental carcinogens. Conversely, they contribute to tumour cell survival by detoxification of numerous products
induced by cancer therapy. The authors designed a large study to investigate the susceptibility and prognostic implications of the
GSTT1 and GSTM1 gene deletions in breast carcinoma. The authors used the polymerase chain reaction to characterise the variation
of the GSTT1 and GSTM1 genes in 309 unrelated Tunisian patients with breast carcinoma and 242 healthy control subjects.
Associations of the clinic-pathologic parameters and the genetic markers with the rates of the breast carcinoma specific overall
survival (OVS) and the disease-free survival (DFS) were assessed using univariate and multivariate analyses. A significant association
was found between gene deletion of GSTT1 and the risk of early onset of breast carcinoma (OR¼1.60, P¼0.02). The lack of GSTT1
gene deletion was significantly associated with poor clinical response to chemotherapy (OR¼2.29, P¼0.03). This association was
significantly higher in patients with axillary’s lymph node-negative breast carcinoma (OR¼12.60, P¼0.005). The null-GSTT1
genotype showed a significant association with increased DFS in this selected population of patients. This association was even higher
in patients carrying both null-GSTT1 and -GSTM1 genotypes. The gene deletion of GSTs may predict not only the early onset of
breast carcinoma but also the clinical response to chemotherapy and the recurrence-free survival for patients with lymph node-
negative breast carcinoma.
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Breast carcinoma is the most frequent malignancy among women,
representing a major health problem in many countries. Family
history of breast carcinoma and reproductive history account for
only 30% of cases (Henderson, 1993; Ghadirian et al, 1998).
Epidemiological studies have suggested that environmental factors
may play a major role in the development of breast carcinoma
(Haris et al, 1992; Henderson, 1993). The potent carcinogens
implicated in breast carcinogenesis are polycyclic aromatic hydro-
carbons (PAHs), aromatic and heterocyclic amines present in the
diet and environmental exposures (Calaf and Russo, 1993;
Dunnick et al, 1995). These were shown to cause mammary
tumours in rodents and to form adducts in human breast cells
(Cavalieri et al, 1988; Byers, 1994; Dunnick et al, 1995; Pfau et al,
1998). Polycyclic aromatic hydro-carbons are activated by
cytochrome P-4501A1(CYP1A1), and the resulting reactive inter-
mediates are detoxified by glutatione-S-transferases (GSTs). These
enzymes are expressed in normal breast tissue as well as in breast
tumours (Sadreih et al, 1996; Lee et al, 1997; Stone et al, 1998).
Individuals who are homozygous for the null-GSTM1 or null-
GSTT1 genotypes lack the respective enzyme functions (Seide-
gaard et al, 1986; Pemble et al, 1994). The null-GSTM1 genotype
appears to be common in several populations, whereas the null-
GSTT1 genotype exhibits population frequencies that depend on
ethnicity (Bell et al, 1993; Nelson et al, 1995; Lin et al, 1998). The
GSTM1 and GSTT1 defects seem to be associated with increased
risk of certain cancers (Rebbeck, 1997; Strange et al, 1998);
however, conflicting data have been observed (Chen et al, 1996;
Baily et al, 1998; Houston, 1999). This may be attributable to
differences in study design and the analysed populations, as well as
to the presence of different confounding factors. The Tunisian
population is known for its relative homogeneity. We analysed the
relationship between gene deletion of GSTM1 and GSTT1 and the
susceptibility to breast carcinoma in this population. Chemother-
apy and radiation therapy after surgery for breast carcinoma
reduce the risk of recurrence and mortality. However, many
patients are not cured with these treatments. Considerable
research has been focused on tumour clinic-pathologic character-
istics that may predict prognosis. Little is known about the Received 7 April 2003; revised 10 July 2003; accepted 24 July 2003
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in reduced treatment efficacy. Both chemotherapy and radiation
therapy largely exert their antineoplastic effects by generating
reactive oxygen products (Hellman, 1993; Weijl et al, 1997). As
these are the proximate cause of tumour cell death in many cases,
the amounts of reactive species that reach tumour cells and have
either direct cytotoxic effects or trigger intracellular apoptotic
pathways is likely to have initial and immediate impact on
treatment efficacy. Thus, interindividual variability in enzymes
that will affect reactive oxygen species (ROS) may have a
significant impact on patient prognosis after treatment.
Several reports highlighted the role of GSTs enzymes in the
detoxification of numerous products induced by cancer therapy
(Hurst et al, 1998; Hayes and Melellan, 1999). GSTT1 and GSTM1
are active in the elimination of several products resulting from
reactive oxidant damage to DNA and lipids, such as organic
epoxides, and hydroperoxides. The reduction of these molecules
by GSTs prevents further oxidant damage within cells. Individuals
lacking each of these enzymes may have reduced removal of
secondary organic oxidation products produced by cancer therapy
and, thus, may have better prognoses. In line with this hypothesis,
we investigated, in a large cohort of 309 breast carcinoma from
whom complete follow-up data were collected, the potential
association of the gene deletion of GSTM1 and GSTT1 enzymes
with tumour clinic-pathologic characteristics and with the
increased risk of relapse and death from breast carcinoma.
MATERIALS AND METHODS
Patients and controls
The gene and allele frequencies of the GSTT1 and GSTM1 genes
were determined in a group of 242 control subjects and 309
patients with breast carcinoma. Controls and patients were
selected from the same population living in the middle coast of
Tunisia. Both the control and patients groups include unrelated
subjects.
Clinical follow-up data were collected on the cohort of the 309
patients recruited from the department of Radiation Oncology and
Medical Oncology of Sousse Hospital (Sousse Tunisia) between
1994 and 2002.
All patients included in this study had primary breast
carcinoma, with unilateral breast tumours. The patients (304
females and five males) had a mean age of 52724 years. The
median of follow-up was 36 months (range, 1–120 months). At
time of analysis, 76 patients relapsed (local or distant recurrence).
Among them, 36 patients died from breast carcinoma (47.3%). A
detailed description of the clinic-pathologic characteristics of this
cohort has been reported elsewhere (Ben Ahmed et al, 2002).
Control subjects (110 females and 132 males) having a mean age
of 41714 years, were healthy blood donors having no evidence of
any personal or family history of cancer (or other serious illness).
Written informed consent was obtained from all subjects.
Patients treated by chemotherapy as a primary treatment:
Among the 309 patients, 140 had chemotherapy as an anticancer
primary treatment. This group includes 122 patients who had
neoadjuvant chemotherapy and 18 patients who received che-
motherapy as a palliative treatment. The chemotherapy induction
was based in all cases on the combination of cyclophosphamide
(100%), 5-fluorouracil (100%) with adriamycin (36%) or epirubi-
cin (51%) or methotrexate (13%). For neoadjuvant treatment,
patients received four or six chemotherapy cycles before surgery.
The clinical response to induction chemotherapy for all cases was
defined according to the following criteria: complete response
when regression of the tumour was total, partial response when the
reduction of tumour size was greater than 50% and poor response
when the reduction of tumour size was less than 50% (tumour size
was measured by the bidimensional product of the horizontal and
vertical dimensions). Lumpectomy or mastectomy was performed
3 weeks after the last cycle of induction chemotherapy; post-
operatively, patients resumed chemotherapy. Consolidative radia-
tion therapy was performed in 26 cases.
DNA extraction
Genomic DNA was extracted from peripheral blood leucocytes by a
salting out procedure (Olerup and Zetterquist, 1992). Briefly, 10ml
of blood was mixed with triton lysis buffer. Leucocytes were spun
down and washed with H2O. The pellet was incubated with
proteinase K at 561C and subsequently salted out at 41C using a
saturated NaCl solution. Precipitated proteins were removed by
centrifugation. The DNA in the supernatant was precipitated with
ethanol. The DNA pellet was dissolved in 400ml sterile distilled
H2O.
Polymorphism analysis of GSTT1 and GSTM1 genes
Polymorphic deletion of the GSTT1 and GSTM1 genes was
revealed by PCR-based assays with b-interferon as a control gene.
In addition to the b-interferon primers (50-GGCACAACAGG-
TAGTAGGCG-30, and 50-GCCACAGGAGCTTCTGACAC-30), two
sequence specific oligonucleotide primers (GSTT1 or GSTM1) were
used for each PCR: for GSTT1, the 30 primer (50-TTCCTTACT
GGTCCTCACATCTC-30) was used in combination with the 50
primer (50-TCACCGGAT CATGGCCAGCA-30). For GSTM1, the 30
primer (50-CTGCCCTACTTG ATTGATGGG-30) was used with the
50primer (50-CTGGATTGTAGCAGATCATGC-30). In all, 30mlo f
PCR reaction mixture was comprised of genomic DNA samples
(100ng), 200mmoll
 1 dNTPs, 1.5mM MgCl2,1  Taq polymerase
buffer, 100pmol of each primer and 0.5U of Taq DNA polymerase
(Amersham, Paris, France). The reaction conditions used with the
thermal cycler (Biometra, Go ¨ttingem, Germany) were as follows:
for GSTT1, the initial incubation at 941C for 4min, followed by 30
cycles of incubation at 941C for 1min; 661C for 1min, and 721C for
1min and followed by a final incubation at 721C for 5min. For
GSTM1, the initial incubation at 941C for 5min, followed by 30
cycles of incubation at 941C for 30s; 601C for 1min, and 721C for
1min and followed by a final incubation at 721C for 5min.
The reaction products were separated on a 2% agarose gel and
stained with ethidium bromide. The absence of amplified GSTT1
(480bp) or GSTM1 (271bp) product (in the presence of the
interferon PCR product (170bp) indicated the respective null
genotype for each.
Statistical analyses
The w
2 test was used to evaluate for a significant association
between disease (breast carcinoma vs controls) and GSTT1 or
GSTM1 genotypes.
Disease-free survival (DFS) was defined as the time from the
date of diagnosis to the first local or distant recurrence or to last
contact. Breast carcinoma-specific overall survival (OVS) was
defined as the time from the date of diagnosis to death if the
patient died from breast carcinoma or to last contact. Six-year
survival rates were estimated, and survival curves were plotted
according to Kaplan and Meier (1958). The differences between
groups were calculated by the log-rank test (Peto et al, 1977).
Clinicopathological parameters were dichotomised as follows:
nodal status (X1 vs no positive lymph node), SBR (Scarff, Bloom
and Richardson) tumour grade (1–2 vs 3), clinical tumour size
(T1–T2 vs T3–T4).
Statistics were performed using SEM-STATISTIQUES software
(Centre Jean Perrin, Clermont–Ferrand, France).
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Polymorphisms in GSTT1 and GSTM1 genes and breast
carcinoma
The distribution of the GSTT1 and GSTM1 genotypes in the patient
and in the control groups is shown in Table 1. The frequency of the
null-GSTT1 genotype was 0.333 in the group of patients with breast
carcinoma and 0.260 in control subjects (OR¼1.42, P¼0.06). No
significant differences in null-GSTM1 distributions were seen
between patients and controls (OR¼0.87, P40.05). The frequency
of the double null-GSTT1-GSTM1 was slightly higher in patients
(0.178 vs 0.149, OR¼1.24), but the difference did not reach
statistical significance. When we stratified the patients according
to their menopause status, we found that the null-GSTT1 genotype
frequency was significantly higher in premenopausal patients than
in controls (0.360 vs 0.260, OR¼1.60, P¼0.02). Thus, there was an
association between the presence of the null-GSTT1 genotype and
the early onset of breast carcinoma. None of the GSTM1 genotypes,
either alone or in combination with GSTT1 genotypes, was
associated with breast carcinoma in the different subgroups.
Prognostic significance of polymorphisms in GSTT1 and
GSTM1 genes
Among the 309 patients with breast carcinoma, 140 had
chemotherapy as an anticancer primary treatment, including 122
patients treated by neoadjuvant chemotherapy. A total of 53
patients were axillary’s lymph node-negative. Table 2 shows the
associations between gene deletion of GSTT1 and GSTM1 and the
clinical response to chemotherapy induction. Poor response to
chemotherapy was seen significantly more frequently in patients
having the ‘present’-GSTT1 genotype compared to those carrying
the null-GSTT1 genotype (OR¼2.29, P¼0.03). This association
seems to be particularly high for patients who were node-negative
(OR¼12.60, P¼0.005). Poor response to chemotherapy was seen
slightly more frequently in patients carrying the ‘present’-GSTM1
genotype than those with the null-GSTM1 genotype, but without
reaching statistical significance (0.516 vs 0.483, P¼0.19).
We were interested in the combined effects that null genotype
for both GSTM1 and GSTT1 may have had on the clinical response
to chemotherapy. Poor response to chemotherapy was significantly
less frequent in patients carrying the double-dose null-GSTT1-
GSTM1 genotype than in patients without (OR¼2.97, P¼0.04).
No patient who was node-negative and carrying the double null-
GSTT1-GSTM1 genotypes had poor response to chemotherapy. In
contrast, 19 patients, among 45 lacking the double null genotypes
had poor clinical response (P¼0.02).
Table 3 shows the clinicopathological characterisation. The
distribution of the clinicopathological markers was in agreement
with previously reported data, indicating that our cohort (309
patients) was representative of breast carcinoma patients. Disease-
free survival and breast carcinoma-specific OVS rates were
estimated and compared by univariate analysis on these clinico-
Table 1 GSTT1 and GSTM1 genotype frequencies in control subjects and in patients with breast carcinoma
Controls (n¼242) All patients (n¼309) PreM (n¼197) PostM (n¼112)
Genotype n (f) n (f) P n (f) P n (f) P
GSTT1
Null 63 (0.260) 103 (0.333) 0.06 71 (0.360) 0.02 32 (0.285) NS
Present 179 (0.740) 206 (0.666) 126 (0.640) 80 (0.715)
GSTM1
Null 138 (0.570) 166 (0.537) NS 110 (0.558) NS 56 (0.500) NS
Present 104 (0.430) 143 (0.463) NS 87 (0.442) 56 (0.500)
GSTT1 and GSTM1 combined
Both Null GTT1-GSTM1 36 (0.149) 55 (0.178) NS 38 (0.193) NS 17 (0.152) NS
GSTT1 and/or GSTM1 Present 206 (0.851) 254 (0.822) NS 159 (0.807) 95 (0.848)
The w
2 test was used to determine whether significant differences (P-value) were observed when the patient group was compared with the control group.
PreM¼premenopausal patients; PostM¼postmenopausal patients; f, frequencies; NS: not significant.
Table 2 Associations between GSTT1 and GSTM1 genetic deletions and clinical response to chemotherapy induction
Chemotherapy response
All patients (n¼140) ALN-negative (n¼53)
Genotype Poor Complete/partial Poor Complete/partial
n (f) n (f) P-value n (f) n (f) P-value
GSTT1
Null 13 (0.217) 31 (0.388) 0.03 01 (0.052) 14 (0.412) 0.005
Present 47 (0.783) 49 (0.612) 18 (0.948) 20 (0.588)
GSTM1
Null 29 (0.483) 47 (0.588) NS 09 (0.474) 19 (0.589) NS
Present 31 (0.516) 33 (0.412) 10 (0.526) 15 (0.441)
GSTT1 and GSTM1 combined
Both Null GTT1-GSTM1 05 (0.083) 17 (0.212) 0.04 00 (0.000) 08 (0.235) 0.02
a
GSTT1 and/or GSTM1 Present 55 (0.917) 63 (0.788) 19 (1.000) 26 (0.765)
The w
2 test was used to determine whether significant differences (P-value) in the clinical response to chemotherapy were observed between carriers of different genotypes. NS:
not significant; f: frequencies; ALN¼axillary’s lymph node-negative.
aFisher’s test was used.
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clinical tumour size, nodal status and tumour grading with DFS
and OVS. No significant differences were observed for age.
When we tested the relationship between the presence of null-
GSTT1 and/or null-GSTM1 genotypes in all 309 patients and the
survival (OVS or DFS), no significant differences were observed
between the different Kaplan–Meier survival curves (data not
shown).
We conducted further analyses to explore whether the GSTs
gene deletion was associated with survival on a selected population
of patients. We selected patients with axillary’s lymph node-
negative from the total patient population. No significant
differences were seen between different OVS curves, indicating
lack of association between GSTs gene deletion and OVS in this
selected population.
Figure 1 shows the breast carcinoma-specific DFS of breast
carcinoma in patients with axillary’s lymph node-negative
according to the presence or absence of the null-GSTT1 and/or
null-GSTM1 genotypes. The DFS was significantly longer in the
group of patients carrying the null-GSTT1 genotype (Figure 1A).
The estimated 3- and 6-year DFS rates in the groups of patients
carrying the ‘present’-GSTT1 genotype or carrying the null-GSTT1
genotype were, respectively, 85 and 61% vs 98 and 83.5% (log-rank
test, P¼0.02).
Although differences in DFS were seen between patients
carrying the ‘present’-GSTM1 genotype and those with null-
GSTM1 genotype, they did not reach statistical significance
(Figure 1B, log-rank test, P¼0.21). When DFS comparison was
made between patients who had both ‘present’-GSTT1 and GSTM1
genotypes and those with both null-GSTT1-GSTM1 genotypes
(Figure 1C), an increase in DFS was seen for patients carrying both
null-GSTT1 and GSTM1 genotypes. The 6-year DFS rate in the
group of patients with ‘present’-GSTT1-GSTM1 genotypes was 65.7
and 87.1% in that of patients with null-GSTT1-GSTM1 genotypes
(log-rank test, P¼0.01).
DISCUSSION
Several studies have addressed the role of GSTT1 and GSTM1 gene
deletions as risk factors in breast carcinoma, but the results are
conflicting (Helzlsouer et al, 1998; Gumundsdottir et al, 2001;
Krajinovic et al, 2001; Mitrunen et al, 2001). The ethnic
heterogeneity of the analysed populations may be among the
confounding factors. Hence, in this study, we assessed the
potential association of these genetic polymorphisms with breast
carcinoma in the Tunisian population, known for its relative
homogeneity. The findings, which showed that GSTs enzymes play
crucial role in the detoxification of numerous products induced by
cancer therapy, prompted us to evaluate the prognostic signifi-
cance of GSTs deletions in breast carcinoma.
The present case/controlled study showed a borderline sig-
nificant increase in the risk of breast carcinoma in unselected
subjects carrying the null-GSTT1 genotype. This association
becomes clearly significant for premenopausal women. Thus the
GSTT1 deletion seems to be associated specifically with the early
onset of breast carcinoma. No direct correlation was found
between polymorphism in the GSTM1 gene and the breast
carcinoma onset in Tunisians. Our data provide evidence against
a substantially increased risk of breast carcinoma associated with
GSTM1 homozygous gene deletion.
Table 3 Clinicopathological characteristics of the 309 breast carcinoma
and the corresponding univariate analysis of death (OVS) and relapse
(DFS)
Breast carcinoma-specific OVS DFS
% 6-year rate P-value 6-year rate P-value
Clinical tumour size
T1–T2 62.28 86.76 o0.03 79.4 o0.0001
T3–T4 37.72 72.05 38.2
Lymph node status
N( ) 54.2 94.11 o0.001 76.47 o0.01
N(+) 45.8 69.12 57.35
SBR grading
1–2 61.2 87.3 o 0.01 59.7 o0.04
3 38.8 58.3 36.1
Age (years)
o50 60.26 80.88 NS 73.5 NS
X50 39.74 86.76 73.5
Six-year survival rates were estimated according to Kaplan and Meier (1958). The log-
rank test (Peto et al, 1977) was used to determine whether significant differences (P-
value) were observed between subgroups of patients. The lymph node status was
determined based on the pathological examination. NS: not significant.
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Figure 1 Breast carcinoma-specific DFS of axillary’s lymph node-negative
breast carcinoma patients according to the presence or absence of the null-
GSTT1 genotype (A), that of null-GSTM1 genotype (B) and that of the
double null-GSTT1-GSTM1 genotype (C). P denotes the log-rank test
value.
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cytotoxic activity of chemotherapy agents. Several studies have
shown that patients treated with a wide range of chemotherapy
agents have marked increases in lipid peroxidation products
(Subramaniam et al, 1993; Look and Musch, 1994; Faber et al,
1995; Faure et al, 1996). All patients of this study were treated
primarily with cyclophosphamide and 5-flurouracil. There is
evidence that these agents, particularly cyclophosphamide, result
in lipid peroxidation and generation of ROS. The mechanism by
which cyclophosphamide kills tumour cell through ROS is
demonstrated by rodent data showing that the lung injury
associated with treatment with cyclophosphamide is attributable
to its ability to generate free radicals (Patel, 1990; Venkatesan and
Chandrakasan, 1995). The GSTT1 and GSTM1 enzymes have been
shown to have removal activity toward lipid hydroperoxides. The
lack of these enzymes could conceivably be associated with better
response to chemotherapy. In this study, we initiate the prognostic
significance evaluation of the GSTs deletions by investigating the
potential association between GSTT1 and GSTM1 gene deletion
and the clinical response to chemotherapy induction. This
evaluation indicated that only GSTT1 gene deletion is associated
with the clinical response to chemotherapy. This prognostic
significance was particularly high for patients with axillary’s
lymph node-negative breast carcinoma. Although no significant
association was found between GSTM1 gene deletion and the
response to chemotherapy, a combined effect of GSTT1 and
GSTM1 gene deletions was seen on the response to chemotherapy
induction. Indeed, none of the patients with lymph node-negative
and carrying the double null-GSTT1-GSTM1 genotype had poor
response to chemotherapy. In studies of haematopoietic cancers,
reduced risk of disease recurrence was noted among children with
acute lymphoblastic leukaemia, who had alleles encoding no or
lower activity for GSTT1, -M1 and -P1 (Stanulla et al, 2000). An
increased therapy-related toxicity among the GSTT1-null patients
with acute myelocytic leukaemia has been shown (Davies et al,
1999). These findings support the hypothesis that patients with
GSTT1-null genotypes have reduced detoxification of therapeutic
agents and, in the case of high-dose therapy for acute myelocytic
leukaemia, worse outcomes. In the present study of primary breast
carcinoma patients, the better response to chemotherapy that was
observed among GSTT1-null patients, who were not treated with
high-dose therapy, can be explained by the increased efficacy of
treatment.
There have been only a few studies of GST genetic poly-
morphism and survival after treatment of breast carcinoma
(Lizard-Nacol et al, 1999; Ambrosone et al, 2001). For the
most part, prior studies were undertaken on a small or
heterogeneous population. In our data, the effect of GSTT1 and
GSTM1 gene deletions on survival after the treatment of breast
carcinoma was not evident in the entire population. The selection
of axillary’s lymph node-negative breast carcinoma allowed
the appearance of a significant association between DFS of
breast carcinoma and the GSTT1 gene deletion. No association
was found with the GSTM1 gene deletion. However, there was an
increase in DFS for patients carrying both gene deletions for
GSTT1 and GSTM1.
In conclusion, this study suggests that GSTT1 gene deletion may
be an attractive susceptibility marker for the early onset of breast
carcinoma. This genetic marker represents not only a predictor of
chemotherapy response but also a prognostic variable for
predicting relapse in patients with lymph node-negative breast
carcinoma.
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